汇宇制药：HYP-6589片联合用药获得药物临床试验申请受理

Core Viewpoint - The announcement indicates that Huiyu Pharmaceutical's wholly-owned subsidiary, Huiyu Haiyue, has received approval from the National Medical Products Administration for a clinical trial application involving HYP-6589 tablets in combination with Osimertinib for treating advanced non-small cell lung cancer with target-driven gene positivity [1] Group 1 - Huiyu Haiyue received the acceptance notice for the clinical trial application on November 21, 2025 [1] - The drug HYP-6589, also known by its research and development code "HY-0006," is intended for use in conjunction with Osimertinib [1] - The focus of the clinical trial is on advanced non-small cell lung cancer that is positive for target-driven genes [1]